Literature DB >> 28960424

Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.

Massimo Breccia1, Gioia Colafigli1, Matteo Molica1, Emilia Scalzulli1, Daniela Diverio1, Roberto Latagliata1, Anna Guarini1, Robin Foà1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28960424     DOI： 10.1002/ajh.24916

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  2 in total

1.  Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.

Authors:  Sandrine Saugues; Céline Lambert; Elisabeth Daguenet; Hyacinthe Johnson Ansah; Ali Turhan; Françoise Huguet; Agnès Guerci-Bresler; Andreï Tchirkov; Dalil Hamroun; Eric Hermet; Bruno Pereira; Marc G Berger
Journal:  Ann Hematol       Date:  2022-08-30       Impact factor: 4.030

Review 2.  CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions.

Authors:  Emilia Scalzulli; Ida Carmosino; Maria Laura Bisegna; Maurizio Martelli; Massimo Breccia
Journal:  Curr Hematol Malig Rep       Date:  2022-10-20       Impact factor: 4.213
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.